Bone Marrow Transplantation News

The FDA announced several regulatory actions the past few weeks.

A phase 2 trial of axatilimab for chronic graft-versus-host disease met its primary endpoint, according to the agent’s manufacturer.

Chronic graft-versus-host disease is a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation.

A man has remained in treatment-free HIV remission for nearly 2 years after receiving a stem-cell transplant to treat a rare and aggressive form of leukemia, researchers reported Wednesday.

For years now, transplant physicians have spoken different languages when referring to a matter of utmost relevance — graft-versus-host disease.

A treosulfan-based reduced-toxicity conditioning regimen has significantly improved hematopoietic cell transplantation outcomes for patients with high-risk thalassemia major and hematologic malignancies.

An oncology financial navigation intervention decreased financial toxicity among patients with blood cancers and their caregivers, according to study results.

The FDA approved omidubicel-onlv, a donor cord blood-based cell therapy, to accelerate neutrophil recovery and reduce the risk for infection among patients with hematologic malignancies undergoing stem cell transplantation.

Reactivation of double-stranded DNA viruses is an important cause of morbidity and mortality after hematopoietic stem cell transplantation.

Miguel-Angel Perales, MD, has been named president of American Society for Transplantation and Cellular Therapy for 2023-2024.